Organon & Co. (OGN) - Stock Analysis
Last updated: Apr 25, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Speculative takeover/momentum catalyst: stock up about 125% over 21 trading days, driven by reports of Sun Pharma's binding $12B all-cash offer and possible final offer, plus VTAMA support from 2026 AAD pediatric atopic dermatitis guidelines.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong cash flow ⢠High leverage ⢠Weak quarter OGN delivered solid full-year profitability and cash flow, but its high leverage and weak quarter highlight elevated balance-sheet risk despite a reasonable valuation.
Price Behavior
Key Price Behavior Insights: ⢠Breakout Momentum ⢠Extended Rally ⢠Key Support Test Support Level: $8.60â$9.20 Resistance Level: $11.26 OGN has broken out strongly over the last month and is showing bullish momentum, but after the steep run to $11.26 it looks extended and must hold the $8.60â$9.20 support band to avoid a sharp pullback.
Sentiment & News
Key News Insights: ⢠Takeover speculation ⢠VTAMA support ⢠Earnings catalyst Organon (OGN) drew heavy attention on takeover rumors after Sun Pharma reportedly made a $12B all-cash offer, while VTAMA data and upcoming Q1 earnings added supportive near-term catalysts.
AI Summary
OGN now looks less like a broken pharma levered value trap and more like an asset-backed special situation, where the real upside comes from a potential strategic transaction and VTAMA/women's health execution, but the heavy debt load means investors should prioritize cash preservation and be wary that any disappointment or takeover headlines fading could quickly erase the rerating.
Description
Organon & Co. develops and commercializes prescription therapies globally, with a significant emphasis on women's health products, a portfolio of biosimilars in immunology and oncology, and established branded medicines across cardiovascular, respiratory, dermatology, bone health and pain management. The company distributes primarily to drug wholesalers and retailers, hospitals, government agencies and managed-care entities. Organon was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 27 | May 4 | OGN | Organon & Co. | Speculative takeover/momentum catalyst: stock up about 125% over 21 trading days, driven by reports of Sun Pharma's binding $12B all-cash offer and possible final offer, plus VTAMA support from 2026 AAD pediatric atopic dermatitis guidelines. | Active | +0.0% |